Showing results (331-340 of 399) with videos related to

Sort By:
Pageof 40
British Journal of Haematology|March 18, 2020
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphomaNathan H Fowler, Loretta Nastoupil, Sven De Vos, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Haematologica|August 1, 2020
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphomaPaolo Strati, Ankur Varma, Sherry Adkins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Bone Marrow Transplantation|August 26, 2014
NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHDL M Curtis, L Grkovic, S A Mitchell, et al.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.
Blood|February 7, 2004
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cellsKouhei Yamashita, Uimook Choi, Patricia C Woltz, et al.
Blood Advances|July 24, 2026
Clinical utility of real-time comprehensive molecular testing in large B-cell lymphomaDai Chihara, Kumudha Balakrishnan, Gita Masand, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 11, 2020
90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's LymphomaKevin C Conlon, Claude Sportes, Martin W Brechbiel, et al.
Pageof 40